For males, 12% and 12% of tests were positive that year. We estimated that screening uptake was 12% and 14% among females, and 4% and 8% among males aged 15–19 and 20–24 in 2018. There was also a gradient of CT rates by ON-MARG quintile, indicating that those with lower SES had higher rates of CT. We also observed a large cluster of CT infection in the vicinity of a local post-secondary instituation. **Conclusion** There is a need for gender-neutral screening guide-lines and changes to the primary care practices to increase routine screening of CT among young males, along with targeted interventions based on the local epidemiology, to curb the epidemic of CT.

Disclosure No significant relationships.

## P474 CASES OF *LYMPHOGRANULOMA* VENEREUM IN CHICAGO, IL, JULY 2016 – APRIL 2017

<sup>1</sup>Irina Tabidze<sup>\*</sup>, <sup>2</sup>Corinne Blum, <sup>1</sup>David Kern, <sup>1</sup>Rajendra Rai, <sup>1</sup>Willie Gaitors, <sup>2</sup>Chad Hendry, <sup>2</sup>Joshua Guttierez, <sup>2</sup>Carol Elazier, <sup>3</sup>Matt Charles, <sup>3</sup>Carlos Morales, <sup>4</sup>Ramona Bhatia. <sup>1</sup>Chicago Department of Public Health, Bureau Hiv/sti, Chicago, USA; <sup>2</sup>Howard Brown Health, Chicago, USA; <sup>3</sup>Illinois Department of Public Health, Chicago, USA; <sup>4</sup>University of Illinois at Chicago, College of Medicine, Chicago, USA

10.1136/sextrans-2019-sti.556

**Background** Lymphogranuloma venereum (LGV) is caused by *Chlamydia trachomatis* (*CT*) serovars L1–L3. The most recent US outbreak of LGV was in 2016 in Michigan in men who have sex with men (MSM) living with HIV.

Methods To better understand LGV epidemiology in Chicago and increase provider awareness, in 2016, the Chicago Department of Public Health (CDPH) introduced a case-based reporting system for MSM with suspected LGV proctitis. Providers were asked to complete standard forms for adult MSM demonstrating symptoms of proctitis. Demographic/clinical and behavioral risk factors data were abstracted from 7/21/16 - 4/30/17. Rectal specimens found to be positive for CT on nucleic acid amplification testing were submitted for LGV laboratory confirmation.

**Results** A total of 50 suspect LGV cases were reported to CDPH; 47 specimens were submitted to for further molecular testing: 19 were confirmed to be LGV, 10 were non-LGV/CT positive, 2 had indeterminate results and 16 were CT-negative. All confirmed cases were from rectal swabs: 21% (4/19) were non-Hispanic Black, 42% (8/19) were non-Hispanic white, 32% (6/19) were Hispanic, and 5% (1/19) were non-Hispanic Asian. The median age was 35 years (range = 21–46 years). Of 19 confirmed cases, 84% (N=16) were HIV (+), and in two cases, HIV was diagnosed at the time of LGV infection. The median CD4 count was 613 cells/ml (range = 311–1170 cells/ml, IQR=238); HIV RNA was <40 copies/ml in 58% (11/19) of cases. Amongst the confirmed cases for which treatment information was available (N=17), all had been empirically treated with doxycycline for 21 days.

**Conclusion** LGV may be suspected in MSM presenting with proctitis symptoms. These data likely underestimate the true local prevalence of LGV in Chicago since reporting was restricted to symptomatic MSM. Improvements in chlamydia case-based surveillance in key populations are critical given the association with LGV and HIV.

Disclosure No significant relationships.

P475 CHLAMYDIA TRACHOMATIS AND NEISSERIA GONORRHOEAE: PREVALENCE AND FACTORS ASSOCIATED AMONG WOMEN WITH HIV IN SÃO PAULO, BRAZIL

<sup>1</sup>Valdir Pinto\*, <sup>2</sup>Zarifa Khoury, <sup>3</sup>Roberto Jose Silva, <sup>3</sup>Mariza Tancredi. <sup>1</sup>Municipal Health Secretariat of São Paulo State Health Secretariat of Sao Paulo, Municipal STD/AIDS Program STI/AIDS Reference and Training Center, São Paulo, Brazil; <sup>2</sup>Municipal Health Secretariat of São Paulo, Municipal STD/AIDS Program, São Paulo, Brazil; <sup>3</sup>State Health Secretariat of São Paulo, STI/AIDS Reference and Training Center – Sao Paulo, Sao Paulo, Brazil

10.1136/sextrans-2019-sti.557

**Background** Our goal was to estimate the prevalences of and risk factors for *Chlamydia trachomatis* (CT) and *Neisseria gonorrhoeae* (NG) among women with HIV.

Methods Cross-sectional study of women with HIV, who were receiving care from sixteen public health services in São Paulo (October/2013 to March/2014). Participants answered a questionnaire including demographic, behavioral, and clinical data. An urine sample was tested for CT and NG, using a polimerase chain reaction. The chi-square test and a logistic regression model were used to test the associations with CT or NG infections.

Results 836 women were included. The mean age was 40.5 ±0.34 years, and the prevalences of CT and NG infections were 1.8% and 0.5%, respectively. The highest prevalences of CT infection were among who were 18-25 years old (15.9%), had black skin color (2.6%), had  $\geq 2$  sexual partners during the last year (7.3%), had a partner who had been imprisoned (3.3%), and not used condoms during the last 6 months (4%). According to clinical characteristics, the highest prevalences were among who had a spontaneous abortion (3.5%), prior STD (3.7%), had been diagnosed with HIV infection during the last year (4.8%), had a CD4+ <350 cells/mm<sup>3</sup> (4.8%), had atypical squamous cells/glandular cells of undetermined significance in their last Pap smear (11.1%), and had positive NG test results (25%). CT infection was associated with CD4+ <350 cells/mm<sup>3</sup> [adjusted odds ratio (ORadj): 24.5], age of 18-25 years (ORadj: 23.2), the non-use of condoms during the last 6 months (ORadj: 10.2), prior STI (ORadj: 9.4), and having  $\geq 2$  sexual partners during last year (ORadj: 6.1).

**Conclusion** Although we observed a low prevalence of CT infection among women with HIV, younger age was associated with a strong risk of infection. Therefore, it may be appropriate to include screening for CT as part of the routine care for this population.

Disclosure No significant relationships.

## P476 PREVALENCE OF CHLAMYDIA AND GONORRHEA AMONG YOUTH IN LOS ANGELES AND NEW ORLEANS RECEIVING FREQUENT TESTING

<sup>1</sup>Erin Keizur<sup>\*</sup>, <sup>2</sup>Cameron Goldbeck, <sup>3</sup>Jasmine Fournier, <sup>2</sup>Sung-Jae Lee, <sup>3</sup>Sue Ellen Abdalian, <sup>2</sup>Mary Jane Rotheram-Borus, <sup>4</sup>Jeffrey Klausner, <sup>2</sup>Ant Cares. <sup>7</sup>UCLA- David Geffen School of Medicine, Infectious Diseases, Los Angeles, USA; <sup>2</sup>UCLA- David Geffen School of Medicine, Psychiatry and Biobehavior, Los Angeles, USA; <sup>3</sup>Tulane University, Pediatrics, New Orleans, USA; <sup>4</sup>UCLA David Geffen School of Medicine and Fielding School of Public Health, Epidemiology, Los Angeles, USA

10.1136/sextrans-2019-sti.558

Background Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) disproportionately affect adolescents, however,